Loading...
XNAS
ATNF
Market cap5mUSD
Jun 10, Last price  
1.04USD
1D
-1.88%
1Q
-11.11%
IPO
-99.97%
Name

180 Life Sciences Corp

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
99.40%
Rev. gr., 5y
%
Revenues
0k
Net income
-6m
L-69.06%
123,764-14,495,440-25,394,046-12,006,760-20,324,648-38,726,259-19,935,112-6,168,177
CFO
-1m
L-86.44%
-497,357-3,919,145-3,318,654-3,871,961-19,371,428-12,127,585-10,922,223-1,480,567
Earnings
Aug 11, 2025

Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
IPO date
Jun 07, 2017
Employees
5
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
5,757
13,583
18,007
Unusual Expense (Income)
NOPBT
(5,757)
(13,583)
(18,007)
NOPBT Margin
Operating Taxes
(296)
(2,349)
943
Tax Rate
NOPAT
(5,461)
(11,234)
(18,950)
Net income
(6,168)
-69.06%
(19,935)
-48.52%
(38,726)
90.54%
Dividends
(8,012)
Dividend yield
480.89%
Proceeds from repurchase of equity
2,573
5,999
11,485
BB yield
-154.43%
-390.14%
-178.27%
Debt
Debt current
148
1,034
1,309
Long-term debt
20
31
Deferred revenue
(31,189,000)
Other long-term liabilities
7
31,189,000
Net debt
(4,437)
(922)
(5,630)
Cash flow
Cash from operating activities
(1,481)
(10,922)
(12,128)
CAPEX
3
Cash from investing activities
Cash from financing activities
4,038
5,908
10,874
FCF
(5,849)
(10,845)
(25,539)
Balance
Cash
4,585
1,976
6,970
Long term investments
Excess cash
4,585
1,976
6,970
Stockholders' equity
(144,440)
(130,245)
(110,294)
Invested Capital
153,846
131,171
122,977
ROIC
ROCE
EV
Common stock shares outstanding
915
379
100
Price
1.82
-55.13%
4.06
-93.70%
64.41
-95.65%
Market cap
1,666
8.34%
1,538
-76.13%
6,442
-94.73%
EV
(2,771)
616
812
EBITDA
(5,449)
(13,478)
(17,898)
EV/EBITDA
0.51
Interest
51
27
Interest/NOPBT